HomeCancer

Cancer

Roche to halt trial for lung most cancers therapy after 'disappointing' outcomes – XM

Roche to halt trial for lung most cancers therapy after 'disappointing' outcomes  XM

$1.6B might await Orion in up to date Merck prostate most cancers deal

Merck & Co. Inc. is getting the unique, world rights from Orion Corp. to develop the oral prostate remedy, ODM-208, which the 2...

Repurposing most cancers drug to stop organ harm in infectious illnesses

Twelve years in the past, most cancers researchers at College of...

Hot Topics